中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
5期
869-870
,共2页
TUVP%间歇性雄激素去势%持续性雄激素去势%晚期前列腺癌
TUVP%間歇性雄激素去勢%持續性雄激素去勢%晚期前列腺癌
TUVP%간헐성웅격소거세%지속성웅격소거세%만기전렬선암
TUVP%Intermittent Androgen Blockade%Continuous Androgen Blockade%Patients with Advanced Prostate Cancer
目的：：探讨TUVP联合间歇性和持续性雄激素去势对改善晚期前列腺癌患者生活质量和总生存率的影响。方法：随机抽取我院136例晚期前列腺癌患者,将其分为两组,对照组69例,采用TUVP联合持续性雄激素去势治疗,观察组67例,采用TUVP联合间歇性雄激素去势治疗；比较两组治疗3个月后的国际前列腺症状评分、生活质量评分及随访一年后总生存率之间的差异。结果：治疗3个月后,观察组患者在国际前列腺评分、生活质量评分及随访一年后的总生存率分别为1.85±0.48,1.85±0.48,89.55,明显优于对照组,差异有统计学意义(P<0.05)。结论：对晚期前列腺癌患者来说,TUVP联合间歇性雄激素去势治疗是安全有效的治疗方法,能明显改善患者的临床症状,提高生活质量,提高癌症患者的总生存率。
目的：：探討TUVP聯閤間歇性和持續性雄激素去勢對改善晚期前列腺癌患者生活質量和總生存率的影響。方法：隨機抽取我院136例晚期前列腺癌患者,將其分為兩組,對照組69例,採用TUVP聯閤持續性雄激素去勢治療,觀察組67例,採用TUVP聯閤間歇性雄激素去勢治療；比較兩組治療3箇月後的國際前列腺癥狀評分、生活質量評分及隨訪一年後總生存率之間的差異。結果：治療3箇月後,觀察組患者在國際前列腺評分、生活質量評分及隨訪一年後的總生存率分彆為1.85±0.48,1.85±0.48,89.55,明顯優于對照組,差異有統計學意義(P<0.05)。結論：對晚期前列腺癌患者來說,TUVP聯閤間歇性雄激素去勢治療是安全有效的治療方法,能明顯改善患者的臨床癥狀,提高生活質量,提高癌癥患者的總生存率。
목적：：탐토TUVP연합간헐성화지속성웅격소거세대개선만기전렬선암환자생활질량화총생존솔적영향。방법：수궤추취아원136례만기전렬선암환자,장기분위량조,대조조69례,채용TUVP연합지속성웅격소거세치료,관찰조67례,채용TUVP연합간헐성웅격소거세치료；비교량조치료3개월후적국제전렬선증상평분、생활질량평분급수방일년후총생존솔지간적차이。결과：치료3개월후,관찰조환자재국제전렬선평분、생활질량평분급수방일년후적총생존솔분별위1.85±0.48,1.85±0.48,89.55,명현우우대조조,차이유통계학의의(P<0.05)。결론：대만기전렬선암환자래설,TUVP연합간헐성웅격소거세치료시안전유효적치료방법,능명현개선환자적림상증상,제고생활질량,제고암증환자적총생존솔。
Objective:To the impact of TUVP combined intermittent or continuous androgen blockade on the quality of life and overall survival for patients with advanced prostate cancer.Methods:A total of 136 advanced prostate cancer patients were selected randomly.They were divided into observation group (n=67) and control group(n=69) . The observation groups treated with TUVP conbined IAB. The control groups treated with TUVP conbined CAB .Compared two groups Treatment of Cancer Quality of Life,international prostate symptom score,a year of overall survival.Results:Three months after treatment, patients treated with TUVP conbined IAB presented with decreased Cancer Quality of Life、international prostate symptom score compared to control group before treatment(P<0.05). A year after treatment, patients treated with TUVP conbined IAB overall survival were improved compared to control group before treatment (P<0.05).Conclusion:TUVP conbined IAB can effectively improve the quality of life for patients with advanced prostate cancer. Improve patient's patients.
